Psoriasis 4 Susceptibility To C1858958
An inherited tendency to develop psoriasis, which causes thick, red, scaly patches on the skin. The severity and age of onset can vary among family members. Ongoing treatment helps control flares and reduce discomfort.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Topical Corticosteroids
First-line topical treatment using corticosteroid creams or ointments to reduce inflammation and suppress immune response in affected skin areas.
Narrowband UVB Phototherapy
Controlled exposure to ultraviolet B light wavelengths to slow skin cell turnover and reduce scaling and inflammation.
Additional treatment options
Stress Management Therapy
Cognitive behavioral techniques and relaxation training to address stress triggers that can exacerbate psoriasis flare-ups.
psychologicalAnti-inflammatory Diet
Dietary modifications emphasizing omega-3 fatty acids, fruits, vegetables while reducing processed foods and alcohol to minimize systemic inflammation.
dietaryDermatology Follow-up
Regular scheduled appointments with dermatologist to monitor disease progression, treatment efficacy, and adjust therapeutic approaches.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Psoriasis 4 Susceptibility To C1858958?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Menter A, Strober BE, Kaplan DH, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019.
Bime C, Menter A, Korman NJ, et al. Comparative effectiveness of biologic therapies for psoriasis: A systematic review and network meta-analysis. Br J Dermatol. 2022.
Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009.
Medication Comparisons
Compare medications used to treat Psoriasis 4 Susceptibility To C1858958. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy